Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Rhea-AI Summary

Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) will release its fourth quarter and full year financial results for 2022 on March 22, 2023, after the market closes. Following the announcement, management will host a conference call at 4:30 p.m. ET to discuss the results and take questions. Rani Therapeutics focuses on oral delivery technologies for biologics and has developed the RaniPill™ capsules aimed at replacing injections with oral dosing. The company has conducted various studies to assess the safety and bioavailability of its products, emphasizing its innovative approach to drug administration.

Positive

• Development of RaniPill™ capsules could transform biologic drug delivery with oral administration.
• Successful completion of preclinical and clinical studies indicates strong safety and tolerability profile.

Negative

• Pending financial results may reveal potential revenue challenges or operational hurdles.

Management to host conference call on Wednesday, March 22 at 4:30 p.m. ET

SAN JOSE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2022 on Wednesday, March 22 after the close of trading. Rani’s management team will host a conference call and webcast beginning at 4:30 p.m. ET.

To access the call by phone, please use this registration link, and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. After the live webcast, the event will be archived for 90 days in the Investor Relations section of Rani’s website at Events & Presentations.

Rani Therapeutics

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill™ capsules, which are a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill™ capsules.  For more information, visit ranitherapeutics.com.

Investor Contact:

investors@ranitherapeutics.com

Media Contact:

media@ranitherapeutics.com

FAQ

What date will Rani Therapeutics announce its 2022 financial results?

Rani Therapeutics will announce its financial results for 2022 on March 22, 2023.

When is the conference call for Rani Therapeutics scheduled?

The conference call for Rani Therapeutics is scheduled for March 22, 2023, at 4:30 p.m. ET.

What is the focus of Rani Therapeutics?

Rani Therapeutics focuses on the oral delivery of biologics and drugs through its RaniPill™ technology.

What is the significance of Rani's RaniPill™ technology?

RaniPill™ aims to replace subcutaneous injections with oral dosing, potentially improving patient compliance.

Is there a link to access the Rani Therapeutics conference call?

Yes, the access link for the conference call can be found in their press release.